| scholarly article | Q13442814 |
| P356 | DOI | 10.1080/09537104.2017.1366974 |
| P698 | PubMed publication ID | 29090618 |
| P50 | author | Geraldine M McCarthy | Q63659503 |
| Richard Conway | Q46153046 | ||
| P2093 | author name string | Claire-Louise Murphy | |
| Dermot Kenny | |||
| Eimear Dunne | |||
| Niamh Redmond | |||
| Geraldine M McCarthy | |||
| Patricia Kavanagh | |||
| Anne Madigan | |||
| John J Carey | |||
| Laura Helbert | |||
| Liz Geraghty | |||
| P2860 | cites work | Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout. | Q51203256 |
| Implications of glycoprotein VI for theranostics. | Q51752386 | ||
| The dimeric platelet collagen receptor GPVI-Fc reduces platelet adhesion to activated endothelium and preserves myocardial function after transient ischemia in mice. | Q51757699 | ||
| Severity of gouty arthritis is associated with Q-wave myocardial infarction: a large-scale, cross-sectional study. | Q51805859 | ||
| Efficacy and Safety of Platelet Glycoprotein Receptor Blockade in Aged and Comorbid Mice With Acute Experimental Stroke. | Q52147721 | ||
| Anti-TNFα agents curb platelet activation in patients with rheumatoid arthritis. | Q53195970 | ||
| Soluble Glycoprotein VI Is Raised in the Plasma of Patients With Acute Ischemic Stroke | Q57306100 | ||
| Sandwich Immunoassay for Soluble Glycoprotein VI in Patients with Symptomatic Coronary Artery Disease | Q57735718 | ||
| The platelet collagen receptor glycoprotein VI is a member of the immunoglobulin superfamily closely related to FcalphaR and the natural killer receptors | Q28145360 | ||
| Platelet-collagen interaction: is GPVI the central receptor? | Q28185377 | ||
| Platelet activation predicts recurrent ischemic events after percutaneous coronary angioplasty: a 6 months prospective study | Q28193902 | ||
| The GPVI-Fc fusion protein Revacept reduces thrombus formation and improves vascular dysfunction in atherosclerosis without any impact on bleeding times | Q28535276 | ||
| Gout | Q30244021 | ||
| Inhibition of Platelet GPVI Protects Against Myocardial Ischemia-Reperfusion Injury | Q30315530 | ||
| The Fab fragment of a novel anti-GPVI monoclonal antibody, OM4, reduces in vivo thrombosis without bleeding risk in rats | Q33374356 | ||
| Dual ITAM-mediated proteolytic pathways for irreversible inactivation of platelet receptors: de-ITAM-izing FcgammaRIIa | Q33376631 | ||
| Measuring soluble platelet glycoprotein VI in human plasma by ELISA. | Q33384477 | ||
| Focusing on plasma glycoprotein VI. | Q33399327 | ||
| Properties of soluble glycoprotein VI, a potential platelet activation biomarker | Q33419547 | ||
| The GPVI-Fc fusion protein Revacept improves cerebral infarct volume and functional outcome in stroke | Q34917692 | ||
| The role of collagen in thrombosis and hemostasis | Q35752946 | ||
| Laminin stimulates spreading of platelets through integrin alpha6beta1-dependent activation of GPVI. | Q35848605 | ||
| Anti-citrullinated protein antibodies contribute to platelet activation in rheumatoid arthritis. | Q35994186 | ||
| 2015 Gout Classification Criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative | Q36049675 | ||
| Fibrin activates GPVI in human and mouse platelets | Q36091308 | ||
| Effects of febuxostat on platelet-derived microparticles and adiponectin in patients with hyperuricemia | Q36331121 | ||
| A crucial role of glycoprotein VI for platelet recruitment to the injured arterial wall in vivo | Q36370457 | ||
| Long-term antithrombotic protection by in vivo depletion of platelet glycoprotein VI in mice | Q36376147 | ||
| Effect of Colchicine on Platelet-Platelet and Platelet-Leukocyte Interactions: a Pilot Study in Healthy Subjects | Q36578681 | ||
| Platelet glycoprotein VI-related clinical defects | Q36957977 | ||
| Improved survival in rheumatoid arthritis: a general population-based cohort study | Q37531008 | ||
| Novel antiplatelet drug revacept (Dimeric Glycoprotein VI-Fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans | Q38492137 | ||
| Glycoprotein VI as a prognostic biomarker for cardiovascular death in patients with symptomatic coronary artery disease | Q39912642 | ||
| The unclosing premature mortality gap in gout: a general population-based study | Q40364511 | ||
| Surface expression of collagen receptor Fc receptor-gamma/glycoprotein VI is enhanced on platelets in type 2 diabetes and mediates release of CD40 ligand and activation of endothelial cells | Q40531263 | ||
| Platelet collagen receptor glycoprotein VI as a possible novel indicator for the acute coronary syndrome | Q44203026 | ||
| Regulation of platelet membrane levels of glycoprotein VI by a platelet-derived metalloproteinase | Q45016543 | ||
| High residual platelet reactivity (HRPR) for adenosine diphosphate (ADP) stimuli is a determinant factor for long-term outcomes in acute ischemic stroke with anti-platelet agents: The meaning of HRPR after ADP might be more prominent in large athero | Q49132617 | ||
| P304 | page(s) | 1-6 | |
| P577 | publication date | 2017-11-01 | |
| P1433 | published in | Platelets | Q1573582 |
| P1476 | title | Increased platelet reactivity as measured by plasma glycoprotein VI in gout |
Search more.